Policy & Regulation
NJ Bio and Aji Bio-Pharma partner to strengthen support for ADC development
1 April 2026 - NJ Bio Inc, a US-based provider of integrated drug discovery and development services, and Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), a Japan-based provider of biopharmaceutical ma...
Alltrna granted approval for first-in-human clinical trial of AP003
1 April 2026 - Transfer RNA (tRNA) developer Alltrna announced on Tuesday that it has received approval to initiate a Phase 1 clinical trial of AP003 in healthy volunteers in Australia.The study has b...
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
...
Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management
31 March 2026 - Cell-free DNA testing company Natera Inc (NASDAQ:NTRA) on Tuesday reported publication of a prospective study in Clinical Cancer Research demonstrating that its Signatera molecular res...
AstraZeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia
31 March 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) on Tuesday reported positive results from its global Phase III clinical programme evaluating efzimfotase alfa f...
Galapagos and Gilead expand collaboration to advance T cell engager programme
31 March 2026 - Belgian biotechnology company Galapagos NV (Euronext Brussels:GLPG) (NASDAQ:GLPG) announced on Tuesday that it has entered into a binding agreement with US biopharmaceutical company Gi...